Recombinant Human TACSTD2/TROP2 protein (rFc Tag)
种属
Human
纯度
>90 %, SDS-PAGE
标签
rFc Tag
生物活性
未测试
验证数据展示
产品信息
纯度 | >90 %, SDS-PAGE |
内毒素 | <0.1 EU/μg protein, LAL method |
生物活性 |
Not tested |
来源 | HEK293-derived Human TACSTD2 protein His27-Thr274 (Accession# P09758) with a rabbit IgG Fc tag at the C-terminus. |
基因ID | 4070 |
蛋白编号 | P09758 |
预测分子量 | 54.2 kDa |
SDS-PAGE | 55-70 kDa, reducing (R) conditions |
组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
TACSTD2 encodes a transmembrane glycoprotein Trop2, that is overexpressed in most carcinomas where it has been associated with cancer cell plasticity, tumor growth, metastasis and prognosis. In humans, congenital mutations of TACSTD2 cause a gelatinous drop-like corneal disease (GDLD), a rare autosomal recessive disease characterized by the development of bilateral corneal amyloidosis and eventually blindness.Overexpression of TROP2/TACSTD2 has been shown to confer a poor prognosis, notably among patients with gynecologic or gastrointestinal tumors. TROP2/TACSTD2 has also been shown to have some impact on the tumor immune microenvironment and may modulate immunotherapy response. In cervical cancer, TROP2 levels were associated with increased intratumoral tumor-infiltrating lymphocytes and programmed cell death-ligand 1 (PD-L1) expression.Conversely, TROP2/TACSTD2-high tumors had lower gene expression of immune cell markers in breast and non–small cell lung cancer and were independently associated with poor response to immune checkpoint inhibitors (ICIs).
参考文献:
1.Lenárt, Sára. et al. (2022) Sci Rep. 12(1):9583. 2.Morgenstern-Kaplan, Dan. et al. (2024) Oncologist. 29(11):e1480-e1491. 3.Abbas, Mahmoud. et al. (2023) Oncol Lett. 26(6):527.